Genmab — August 2020

[Bulder]

Nok derfor Winkel har cuttet 3 år af visionen

[Bulder]

Og Hutchings tale om "indsprøjtning". Vist ikke andre der er sc.

[Solsen]

Ja det lyder som hånd i handske

[Bulder]

Og tak for linket, butterboy. Herligt med disse patienthistorier - ligesom med dara i gamle dage.

[Solsen]

Ja meget positivt,
at se at der er menneskeskæbner der nyder godt af Genmabs innovation. At vi andre nyder kursstigningerne blegner i den forbindelse.

[GeorgeBest]

Dejlig artikel, tak for den butterboy

[transalp]

Hold da op, dejlig læsning. Tak butterboy.. der er vitterlig meget godt i vente..

[E_L]

GEN1044 (DuoBody-CD3x5T4) started recruiting in July https://www.clinicaltrials.gov/ct2/history/NCT04424641?A=1&B=2&C=merged#StudyPageTop

[E_L]

GEN1046 still steadily adding locations, all recruiting https://www.clinicaltrials.gov/ct2/history/NCT03917381?A=9&B=10&C=merged#StudyPageTop

[E_L]

Enapotamab almost all recruiting as well https://www.clinicaltrials.gov/ct2/history/NCT02988817?A=16&B=17&C=merged#StudyPageTop

[Darvin]

Mht epcoritamab, så tåler denne genlæsning. “Jeg har aldrig set så potent et lægemiddel til den her type patienter“ og “ lige så effektiv som CART-T og mere sikker” https://haematologisktidsskrift.dk/sygdomme/lymfoma/720-subkutant-bispecifikt-cd3-cd20-antistof-mulig-konkurrent-til-car-t.html

[Don_Joning]

puha Darvin det er jo NSFW materiale du deler der

[Bulder]

De omtaler ikke den okulare toksicitet https://haematologisktidsskrift.dk/sygdomme/myeloma/739-dansk-optimisme-efter-ema-godkendelse-af-ny-myelomatose-behandling.html

[lahn1]

NSFW, Not Suitable For Minors ?

[nohope]

Normalt betyder det Not Suitable For Work(på Reddit), men hvorfor det skulle være det her, det aner jeg ikke.

[lahn1]

Nej det for mit ?

[lahn1]

Nej derfor mit ?

[E_L]

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs https://investors.immatics.com/news-releases/news-release-details/immatics-announces-european-clinical-expansion-its-adoptive-cell

[E_L]

Immatics’ clinical product class ACTengine is a personalized approach for patients with advanced solid cancers. Patient’s own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics’ cancer targets identified by its proprietary XPRESIDENT target discovery platform.

[E_L]

it is now 2 years ago that Genmab "gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT technology" Would be nice if we could hear a bit on progress on CMD